The NextGenerat ion of DrugDel ivery: Where arewe headed?is awarded to

What's

next?

BIOTECH STILL ADVANCING Innovation in biopharmaceutical drug product developmentis today, often driven by small biotech. A healthy venturecapital market is now enabling small biotech companies totake their new treatments and products all the way throughto commercialization for niche indications. While larger companies typically have the experience in-house to navigate complex regulatory processes and theability to scale manufacturing flexibly to meet marketdemand, small and virtual biotech companies tend to lackthis expertise due to their size and focus.

The healthcare industry urgentlyneeds to produce innovative newtherapies if it is to overcome itscritical, long-term challenge, ie therevenue gap produced by theindustry’s failure to developsufficient, new, patent-protectedmedical therapies to offset therevenues lost as existing productslose their patent protection

Big Picture Outlook According to markets & Markets, the drug deliverytechnology market is expected to reach USD $1,669.4billion by 2020, growing at a CAGR of 7.2% during theforecast period. Geographically, Asia is projected to growthe most during this period. Regarding routes ofadministration, the market is predominantly segmentedinto oral, injectable, topical, nasal, ocular, pulmonary,implantable, and transmucosa. From 3-D printing, to non-oral delivery of biologics, to advances in nanotechnology,the future for drug delivery is ripe with innovation, butwhat is likely primed for market success? With the increasing prevalence of chronic diseases, aswell as demand for biologics (notably peptides),technological advancements, and new product launches,these are some of the main factors driving growth in thedrug delivery technology market. Additionally, self-administration & home care and an increased demand forbiosimilars and generic drugs offer significant growthopportunities for drug delivery manufacturers. In a nutshell, there will be a significant growth in bothcommercial delivery technologies and whacky novelapproaches flooding the market over the next few years.

Starting from Scratch Worth it? Developing a new drug that receives market approvalcan cost $2.6 billion, according to the Tufts Center for theStudy of Drug Development. Given the high costsinvolved in the drug development process, formulatingproducts that improve delivery has clear cost implicationsfor the industry as well the patient experience. Certainfactors play a part – bioavailability, drug release profileand effectiveness. Is the product for self-administration,likely to be for emergency use? Is it for a child orsomeone with swallowing issues such as the elderly?Does it need to be a slow release formula or take theform of suppositories? Addressing patient requirementscan make the difference between a drug being takencorrectly and not being taken at all, which may haveadverse effects on the health of the patient..

Biologics Thriving? Biologics are expanding rapidly (BCC Research statesthat the global market value for biologics is expected toreach $252 billion this year) especially within the peptideand protein areas. Commercial scale-up manufacturingcontinues to pose a problem due to the complexities ofthe products however the delivery market opportunitiesare plentiful. There are some exciting developmentswithin oral delivery of peptides and proteins, which someconsider the holy grail of drug delivery.

Size Doesn’t Matter? The development of nanomedicines (including utilizationof nanocrystals, nanoparticles, liposomes) has increasedwith conditions such as cancer, cardiovascular diseaseand obesity benefitting from the development of this formof drug delivery. There are also significant advanceswithin targeted and localized delivery, opening up a newwave of products potential for drug manufacturers, not tomention developing modified release products.

And the Rest? Another trend we are seeing is the combination oftechnology and healthcare. Companies such as Googleare partnering with pharmaceutical manufacturers to aidin the diagnosis and understanding of biomarkers and toenable patients to access data more conveniently. As themarket moves forward, expect to see an increase in theuse of mobile devices and apps to capture data that mayhelp to increase the health of the population and capturetrends for education, care, adherence to treatmentregimens and convenient drug delivery. Additionally, there are many more delivery technologiesdriving innovation as we know it, but have yet tobe commercially adopted. However, these remainpromising opportunities for industry in 2020 and beyond.

Are you looking to improve drug performance,bioavailability and patient adherence? Would you liketo reduce dosage, cost and time-to-market? Join the drug development industry’s leading drugdevelopment specialists this January at the 2020 GlobalDrug Bioavailability Enhancement Summit in New York,NY (Jan 28-29, 2020).

The 2020 Summit will showcase industry’s latestformulation and delivery technologies for enhancingsolubility and maximizing bioavailability. 2020’s Summitwill share cutting edge research on the development,characterization and manufacture of formulations thatspan multiple modalities. Additionally, attendees will hearfrom 30+ senior drug bioavailability pioneers and networkwith 120+ senior drug development innovators.

www.curtiscoulter.com/bioavailability